Pioneering Personalized Precision Medicine: Direct-to-Tumor Interventional Radiology at Envita Medical Centers

Abstract

This study highlights the noteworthy response of a 67-year-old male patient presenting with Stage 4 Metastatic high-grade poorly differentiated small cell type neuroendocrine carcinoma who was treated at Envita Medical Centers using their proprietary treatment technology. Treatment of neuroendocrine neoplasms (NENs) is challenging due to the heterogeneous nature of these tumors, their variable therapeutic response, generally poor prognosis, and the need for a multidisciplinary care team. Envita has pioneered a minimally invasive novel technology known as the Chemo Immuno Precision Injection (CIPI TM ) within their Interventional Radiology Oncology Department (EnvitaIR TM ). CIPI TM , an innovative and advanced variation of transarterial chemoembolization (TACE), is a unique, proprietary, image-guided, direct-to-tumor drug delivery platform designed for genetically targeted, precise, personalized chemo- and immuno-therapy. CIPI TM also incorporates chemo-adjunctive agents to enhance treatment effectiveness, facilitating precise tumor targeting while simultaneously activating systemic immunotherapy to combat any distant metastases and circulating tumor cells. In contrast to systemic drug delivery where only a minuscule fraction of the drug reaches the tumor site, CIPI TM directs 95% - 100% of the targeted medication into the tumor. Envita’s use of interventional radiology represents a leap forward in cancer treatment, specifically drug targeting and delivery, offering patients a highly personalized, minimally invasive alternative to traditional surgery and radiotherapy, especially in inoperable regions and in cases where patients have failed the standard NCCN (National Comprehensive Cancer Network) guideline recommendations, an area not unfamiliar to interventional radiology. Innovative personalized medication combinations, image-guided technology, as well as drug targeting using personalized medicine offered at Envita Medical Centers with techniques such as CIPI TM , have resulted in proven, exceptional results for many challenging cases with improved patient outcomes. The results achieved for this patient clearly demonstrate the effectiveness of personalized targeted drug delivery within interventional oncology. Envita’s overall response rate, based on measuring patient response outcomes as well as leading disease indicators including circulating tumor cells and mutant allele frequency, was 72% based on an analysis of 199 late-stage cancer patients treated at Envita Medical Centers over a two-year period. This rate was only 0% - 2% for patients undergoing standard of care because there were no surviving patients in most cases, resulting in a 35-fold improvement in overall response rate for Envita patients compared to those undergoing standard of care [1] . These results are especially significant because approximately 95% of patients coming to Envita present with Stage 3 or Stage 4 cancer; most have previously failed standard of care and hence represent the most challenging cohort to treat [1] . Patient outcomes at Envita highlight the key attributes of personalized precision therapy leading to an enhanced quality of life and longevity: targeting the tumor’s genetic and molecular profile, direct-to-tumor drug delivery capability, as well as rigorous evaluation and prompt, adaptable care.